Sunday, August 19, 2018 7:25:46 PM
I believe when you combine the above with the 505(b) fast track and the decades of safety info from the primary active ingredient that IPIX mgt was looking at making this something of a P2/P3 trial. FDA already has lots of empirical data that the drug is very safe, the virgin trial patients will show exactly how efficacious Prurisol alone will treat psoriasis, we have lots of feedback on quality of life improvement, so what is left to prove from a P3?
Why not have a broad allowance for doctors to request Prurisol with the stipulation that they have to provide feedback of results. This would allow FDA to see if Prurisol doesn't work when patients had previously taken a different psoriasis treatment, if they all had quality of life improvement as to itching, etc.
Would be right in line with Leo's thinking of cutting costs when possible so he believed taking a larger and more detailed P2b trial would greatly pay off with not needing an overly large or having a long-delayed P3 allowed should a P3 be deemed necessary.
I think the initial P2b top end results PR will also include some data regarding some secondary endpoints which will greatly enhance the efficacy PASI number alone.
Still excited, confident, and sure the science will win out.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM